Skin Bacteria Feeds Cancer Cells in Patients With Lymphoma

While bacteria in the skin is normally a good thing - it keeps the body safe from pathogens and promotes a healthy immune system - patients with lymphoma may find skin bacteria is their enemy.

New research from the University of Copenhagen found that the toxins from staphylococcus bacteria, or "staph," actually enables cancer cells to hijack healthy cells and spread disease in lymphoma patients.

"We have gained important insight into the processes that activate cancer cells and make them grow," said Professor Niels Ødum, from the University of Copenhagen. "Patients’ frequent bacteria infections might not be a mere side effect of the disease – on the contrary, toxins in the bacteria actually ‘benefit’ cancer cells."

Lymphoma and skin

Bacterial infections are more common in lymphoma patients, as the skin becomes fragile and susceptible to disease because of the cancer.

The current study reveals that skin bacteria in some patients with lymphoma actually causes cancer cells to change in the body's immune defense system, weakening its ability to fight off the very cells causing its demise.

In patients with skin lymphoma - a rare type of cancer - threatening bacteria could worsen a patient's condition more rapidly than normal. Therefore, researchers hope to identify which type of bacteria produce harmful, cancer-spreading toxins so they can properly treat at-risk patients with antibiotics.

Source: University of Copenhagen

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap